SOUTH SAN FRANCISCO, CA, January 5, 2026 – Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for cancer, today announced that David J. Earp, J.D., Ph.D., president and chief executive officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 5:00 p.m. PT.
Dr. Earp will provide an overview of the company’s pipeline, including CID-078, a first-in-class oral macrocyclic cyclin A/B RxL inhibitor in Phase 1 clinical development for patients with advanced solid tumors, and CID-165, a first-in-class oral macrocyclic cyclin D1 RxL inhibitor, with potential applications in malignancies, including ER-positive breast cancer and lymphomas.
About Circle Pharma
Circle Pharma is a clinical-stage biopharmaceutical company harnessing the power of macrocycles to develop next-generation targeted therapies for cancer. The company’s proprietary MXMO™ platform overcomes key challenges in macrocycle drug development, enabling the creation of intrinsically cell-permeable and orally bioavailable therapies, including for historically undruggable targets. Circle Pharma’s pipeline is focused on targeting cyclins, key regulators of the cell cycle that drive many cancers. The company’s lead program, CID-078, is a cyclin A/B RxL inhibitor in Phase 1 clinical development for patients with advanced solid tumors. Circle Pharma is based in South San Francisco, CA. For additional information, please visit us at circlepharma.com and follow us on LinkedIn and X.
Contacts:
Media:
Josie Butler
1AB
Investors:
Steve Klass
1AB
SOUTH SAN FRANCISCO, CA, December 17, 2025 – Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for cancer, today announced the nomination of CID-165, a first-in-class, orally bioavailable macrocyclic cyclin D1 RxL inhibitor, as the development candidate for its second oncology program.
Cyclin D1 is a regulatory protein that plays a crucial role in cell cycle progression and is overexpressed or translocated in malignancies, including ER-positive breast cancer and lymphomas. In these cancers, cyclin D1 drives cell proliferation by binding to the tumor suppressor retinoblastoma protein (Rb) leading to uncontrolled cell division. In preclinical studies, CID-165 has been shown to potently and selectively disrupt the cyclin D1-Rb interaction allowing Rb to remain active and suppress cancer cell proliferation. CID-165 demonstrates robust anti-tumor activity in cyclin D1-driven preclinical cancer models including in combination with other therapies such as CDK4/6-dual inhibitors, CDK4-selective inhibitors, and endocrine therapies.
“Cyclin D1 has long been recognized as a key oncogenic driver across many solid tumors and hematologic malignancies, yet it has remained an elusive direct therapeutic target,” said Marie Evangelista, Ph.D., senior vice president and head of cancer biology at Circle Pharma. “Our MXMO™ platform has allowed us to design a novel macrocyclic molecule, CID-165, with the precision and selectivity needed to directly block cyclin D1-Rb signaling while minimizing effects on related cyclins, such as cyclin D3, an approach aimed at reducing side effects commonly observed with dual CDK4/6 inhibitors.”
“Despite the transformative impact of CDK4/6 inhibitors for the treatment of ER-positive breast cancer, many patients eventually experience disease progression or adverse events that impact their quality of life,” said Anne Borgman, M.D., chief medical officer of Circle Pharma. “CID-165 is designed to address these limitations through selective inhibition of cyclin D1, a central driver of tumor proliferation, while avoiding adverse events associated with broader CDK4/6 blockade. We look forward to advancing CID-165 toward IND submission in late 2026 and potentially translating the compelling preclinical activity into benefit for patients.”
About Circle Pharma
Circle Pharma is a clinical-stage biopharmaceutical company harnessing the power of macrocycles to develop next-generation targeted therapies for cancer. The company’s proprietary MXMO™ platform overcomes key challenges in macrocycle drug development, enabling the creation of intrinsically cell-permeable and orally bioavailable therapies, including for historically undruggable targets. Circle Pharma’s pipeline is focused on targeting cyclins, key regulators of the cell cycle that drive many cancers. The company’s lead program, CID-078, is a cyclin A/B RxL inhibitor in Phase 1 clinical development for patients with advanced solid tumors. Circle Pharma is based in South San Francisco, CA. For additional information, please visit us at circlepharma.com and follow us on LinkedIn and X.
Contacts:
Media:
Josie Butler
1AB
Investors:
Steve Klass
1AB
SOUTH SAN FRANCISCO, CA, December 1, 2025 – Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for cancer, today announced the appointment of Anne E. Borgman, M.D., as chief medical officer. Dr. Borgman is an accomplished chief medical officer, business executive, scientific advisor and board director with more than 20 years of experience devising and executing clinical development strategies that have led to multiple oncology drug approvals.
“Dr. Borgman joins Circle with an established track record of leading clinical development teams to successful oncology drug approvals in both the U.S. and EU. Her ability to translate strong science into meaningful therapies for patients is exceptional,” said David J. Earp, J.D., Ph.D., president and chief executive officer of Circle Pharma. “Her leadership and deep experience will be instrumental as we continue the clinical development of our first-in-class cyclin A/B RxL inhibitor, CID-078, advance our cyclin D1 into the clinic, and prepare for the next stages of growth at Circle.”
“Circle Pharma’s MXMO™ platform is opening the door to a promising new class of targeted macrocycle therapies, with the potential to address some of the most challenging and impactful cancer targets such as the cyclins,” said Dr. Borgman. “I’m thrilled to join this talented team and to help guide the clinical development of programs that could make a real difference for patients with few treatment options.”
Prior to joining Circle, Dr. Borgman served as chief medical officer of Sutro Biopharma, where she advanced the company’s lead asset into pivotal trials in ovarian cancer and infant leukemia. Before that, Dr. Borgman served as vice president and therapeutic area lead, oncology, hematology, and transplant, at Jazz Pharmaceuticals, where she was responsible for global drug development for four marketed products (Defitelio®, VYXEOS ®, ZEPZELCA® and RYLAZE®), and drug development plans for several emerging targets. Previously, Dr. Borgman was vice president, clinical research & development at Exelixis, where she helped lead the global development for cabozantinib and oversaw the development and execution of multiple Phase 3 clinical trials. She has also held leadership positions in oncology drug development at KaloBios Pharmaceuticals, Talon Therapeutics (formerly Hana Biosciences), and Abbott Laboratories, where she created the early development strategies for venetoclax and veliparib while serving as global project head.
Dr. Borgman currently serves on the board of directors of clinical-stage oncology companies NextCure, Curis, and NiKang. Dr. Borgman received an M.D. from Loyola University Chicago Stritch School of Medicine and completed a residency in pediatrics at Baylor College of Medicine and a fellowship in pediatric hematology-oncology and bone marrow transplantation from the David Geffen School of Medicine at UCLA. She received her B.S. in biochemistry from University of Illinois.
About Circle Pharma
Circle Pharma is a clinical-stage biopharmaceutical company harnessing the power of macrocycles to develop next-generation targeted therapies for cancer. The company’s proprietary MXMO™ platform overcomes key challenges in macrocycle drug development, enabling the creation of intrinsically cell-permeable and orally bioavailable therapies, including for historically undruggable targets. Circle Pharma’s pipeline is focused on targeting cyclins, key regulators of the cell cycle that drive many cancers. The company’s lead program, CID-078, is a cyclin A/B RxL inhibitor in Phase 1 clinical development for patients with advanced solid tumors. Circle Pharma is based in South San Francisco, CA. For additional information, please visit us at circlepharma.com and follow us on LinkedIn and X.
Contacts:
Media:
Josie Butler
1AB
Investors:
Steve Klass
1AB
SOUTH SAN FRANCISCO, CA, November 4, 2025 – Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for cancer, today announced management will participate in upcoming investor conferences in November:
LifeSci Growth & Innovation Summit
November 17, 2025
Participants: David J. Earp, J.D., Ph.D., president and chief executive officer; Rob Lauzen, chief financial officer
Location: London, UK
Jefferies Global Healthcare Conference – London
November 18-20, 2025
Participants: David J. Earp, J.D., Ph.D., president and chief executive officer; Rob Lauzen, chief financial officer
Location: London, UK
About Circle Pharma
Circle Pharma is a clinical-stage biopharmaceutical company harnessing the power of macrocycles to develop next-generation targeted therapies for cancer and other serious illnesses. The company’s proprietary MXMO™ platform overcomes key challenges in macrocycle drug development, enabling the creation of intrinsically cell-permeable and orally bioavailable therapies, including for historically undruggable targets. Circle Pharma’s pipeline is focused on targeting cyclins, key regulators of the cell cycle that drive many cancers. The company’s lead program, CID-078, is a cyclin A/B RxL inhibitor in Phase 1 clinical development for patients with advanced solid tumors. Circle Pharma is based in South San Francisco, CA. For additional information, please visit us at circlepharma.com and follow us on LinkedIn and X.
Contacts:
Media:
Josie Butler
1AB
Investors:
Steve Klass
1AB
SOUTH SAN FRANCISCO, CA, November 3, 2025 – Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for cancer, today announced the appointment of Rob Lauzen as chief financial officer. Mr. Lauzen brings deep financial expertise and broad experience within the life sciences industry, having most recently served as chief financial officer of Prilenia Therapeutics, where he oversaw all aspects of the company’s capital strategy, finance, and investor relations functions.
“We are thrilled to welcome Rob to the Circle Pharma leadership team,” said David J. Earp, J.D., Ph.D., president and chief executive officer of Circle Pharma. “This is an exciting time for Circle as we advance our lead program, CID-078, through Phase 1 clinical development and continue to expand our pipeline of first-in-class oral macrocycle therapeutics that target cyclins — key drivers of cancer that have long been considered undruggable. Rob’s proven expertise in corporate finance, capital markets, and strategic planning will be instrumental as we build on our strong momentum and position the company for long-term growth.”
Prior to serving as chief financial officer of Prilenia Therapeutics, Mr. Lauzen was vice president, investor relations and head of financial planning & analysis at Dyne Therapeutics. Earlier, Mr. Lauzen held roles in the healthcare investment banking group at Morgan Stanley, where he advised clients on a broad range of strategic and financing needs, executing over $185 billion in M&A transactions and over $10 billion of equity offerings. Mr. Lauzen holds a B.A. in engineering sciences from Dartmouth College.
“I’m excited to join Circle Pharma at such a pivotal stage in its evolution,” said Mr. Lauzen. “With a strong scientific foundation and a clear focus on cyclins that are implicated in large populations of cancer patients, Circle is well positioned to deliver transformative new therapies. I look forward to supporting the team’s mission to translate this groundbreaking science into meaningful benefits for patients and value for our stakeholders.”
About Circle Pharma
Circle Pharma is a clinical-stage biopharmaceutical company harnessing the power of macrocycles to develop next-generation targeted therapies for cancer and other serious illnesses. The company’s proprietary MXMO™ platform overcomes key challenges in macrocycle drug development, enabling the creation of intrinsically cell-permeable and orally bioavailable therapies, including for historically undruggable targets. Circle Pharma’s pipeline is focused on targeting cyclins, key regulators of the cell cycle that drive many cancers. The company’s lead program, CID-078, is a cyclin A/B RxL inhibitor in Phase 1 clinical development for patients with advanced solid tumors. Circle Pharma is based in South San Francisco, CA. For additional information, please visit us at circlepharma.com and follow us on LinkedIn and X.
Contacts:
Media:
Josie Butler
1AB
Investors:
Steve Klass
1AB
Oral macrocyclic cyclin D1 RxL inhibition demonstrates potent and selective disruption of cyclin D1–Rb interaction with robust anti-tumor activity in multiple cancer models
Nomination of development candidate expected by year-end 2025
SOUTH SAN FRANCISCO, CA, October 23, 2025 – Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for cancer, today presented preclinical data related to the company’s cyclin D1 development program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The data highlight the therapeutic potential of Circle Pharma’s first-in-class oral macrocyclic inhibitors to preserve retinoblastoma protein (Rb) tumor-suppressor activity by selectively blocking its interaction with cyclin D1, a key driver of cell cycle progression and proliferation in multiple hematological and solid tumor cancer types.
“Cyclin D1 has long been recognized as a key driver in many cancers, but it has remained an elusive direct therapeutic target,” said Marie Evangelista, Ph.D., senior vice president and head of cancer biology at Circle Pharma. “Using our MXMO™ platform, we have engineered orally bioavailable, cell-permeable macrocycles that selectively inhibit cyclin D1-Rb binding while sparing related isoforms such as cyclin D3—an approach aimed at reducing hematologic toxicities commonly observed with dual CDK4/6 inhibitors. These data mark a significant step forward in developing novel, macrocycle-based therapies for patients with cyclin D1-driven cancers.”
“We are excited by the strong selectivity and anti-tumor activity we’re seeing across multiple cyclin D1-driven cancer models including mantle cell lymphoma and ER-positive breast cancer,” said David J. Earp, J.D., Ph.D., president and chief executive officer of Circle Pharma. “Our approach has the potential to open a new class of therapeutics for patients, including for use in combination with other therapies, and we are on track to declare a development candidate for our cyclin D1 program by end of 2025.”
Presentation Highlights:
In cyclin D1-dependent preclinical tumor models, Circle’s oral macrocyclic cyclin D1 RxL inhibitors:
The poster presentation will be made available on the Circle Pharma website at https://circlepharma.com/publications.
About Circle Pharma’s Oral Cyclin D1 RxL Inhibitor Program
Cyclin D1 is a regulatory protein that plays a crucial role in cell cycle progression and is overexpressed in many solid tumors and hematologic malignancies. In these cancers, the cyclin D1/CDK4 complex drives cell proliferation by binding to the tumor suppressor retinoblastoma protein (Rb) and promoting its phosphorylation and inactivation. Using its MXMO™ platform, Circle Pharma has developed oral macrocyclic inhibitors that potently and selectively disrupt the cyclin D1-Rb interaction, demonstrating robust anti-tumor activity in cyclin D1-driven cancers.
About Circle Pharma
Circle Pharma is a clinical-stage biopharmaceutical company harnessing the power of macrocycles to develop next-generation targeted therapies for cancer and other serious illnesses. The company’s proprietary MXMO™ platform overcomes key challenges in macrocycle drug development, enabling the creation of intrinsically cell-permeable and orally bioavailable therapies, including for historically undruggable targets. Circle Pharma’s pipeline is focused on targeting cyclins, key regulators of the cell cycle that drive many cancers. The company’s lead program, CID-078, is a cyclin A/B RxL inhibitor in Phase 1 clinical development for patients with advanced solid tumors. Circle Pharma is based in South San Francisco, CA. For additional information, please visit us at circlepharma.com and follow us on LinkedIn and X.
Contacts:
Media:
Josie Butler
1AB
Investors:
Steve Klass
1AB
SOUTH SAN FRANCISCO, CA, October 14, 2025 – Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for cancer, today announced an upcoming poster presentation highlighting the preclinical anti-tumor potential of cyclin D1 RxL inhibition at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held from October 22 – 26, 2025, in Boston, MA.
Details of the presentation are as follows:
Title: First-in-class Oral Macrocyclic Cyclin D1-selective Inhibitors Demonstrate Anti-Tumor Activity in Cyclin D1-dependent Tumors
Session: Poster Session A
Date & Time: Thursday, October 23, 12:30-4:00 p.m. ET
About Circle Pharma’s Oral Cyclin D1 RxL Inhibitor Program
Cyclin D1 is overexpressed in certain solid tumors and hematologic malignancies. In these cancers, the cyclin D1/CDK4 complex drives cell proliferation by binding to the tumor suppressor retinoblastoma protein (Rb) and promoting its phosphorylation and inactivation. Using its MXMO™ platform, Circle Pharma has developed oral macrocyclic inhibitors that potently and selectively disrupt the cyclin D1-Rb interaction, demonstrating robust anti-tumor activity in cyclin D1-driven cancers.
About Circle Pharma
Circle Pharma is a clinical-stage biopharmaceutical company harnessing the power of macrocycles to develop next-generation targeted therapies for cancer and other serious illnesses. The company’s proprietary MXMO™ platform overcomes key challenges in macrocycle drug development, enabling the creation of intrinsically cell-permeable and orally bioavailable therapies, including for historically undruggable targets. Circle Pharma’s pipeline is focused on targeting cyclins, key regulators of the cell cycle that drive many cancers. The company’s lead program, CID-078, is a cyclin A/B RxL inhibitor in Phase 1 clinical development for patients with advanced solid tumors. Circle Pharma is based in South San Francisco, CA. For additional information, please visit us at circlepharma.com and follow us on LinkedIn and X.
Contacts:
Media:
Josie Butler
1AB
Investors:
Steve Klass
1AB
SOUTH SAN FRANCISCO, CA, September 25, 2025 – Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for cancer, today announced an upcoming poster presentation highlighting the potential of CID-078 as a novel therapeutic option in pediatric cancers at the American Association for Cancer Research (AACR) Special Conference on Pediatric Cancer, taking place from September 25-28 in Boston, MA. CID-078 is a first-in-class, orally bioavailable macrocyclic cyclin A/B RxL inhibitor that is currently being evaluated in a Phase 1 clinical trial for patients with advanced solid tumors.
The presentation, based on a collaboration between Circle Pharma and Children’s Cancer Institute (Sydney, Australia), will focus on the novel mechanism of action of CID-078 for cancers driven by high E2F activity including those with alterations in the tumor suppressor genes RB1 or CDKN2A/B, as well as the prevalence of these biomarkers across a diverse range of pediatric cancer types. In addition, the presentation will outline new preclinical data on the correlation between CID-078 sensitivity and RB1 and E2F biomarker status in a database of pediatric tumor samples from The ZERO Childhood Cancer Precision Medicine Program.
“We believe CID-078 may represent a promising new therapeutic option for pediatric cancers with certain defined molecular drivers,” said Michael C. Cox, PharmD, MHSc, BCOP, senior vice president and head of early development at Circle Pharma. “These findings may inform strategies for real-time patient identification and stratification in potential future pediatric studies of CID-078. Presenting these data generated in collaboration with Children’s Cancer Institute during Childhood Cancer Awareness Month reinforces our commitment to advancing the development of our therapies for patients who urgently need new options.”
Details of the presentation are as follows:
Title: Investigating the Cyclin A/B RxL Inhibitor CID-078 in Pediatric Cancers with RB1 Loss and High E2F1
Abstract Number: B021
Session: Poster Session B
Date & Time: Friday, September 26, 5:00-7:00 p.m. ET
Presenting Author: Chelsea Mayoh, Children’s Cancer Institute, Lowy Cancer Centre, UNSW Sydney, Kensington, Australia
About CID-078, Circle Pharma’s Oral Cyclin A/B RxL Inhibitor Program
CID-078 is an orally bioavailable macrocycle with dual activity blocking protein-protein interactions between both cyclins A and B and key substrates that bind to them via conserved RxL motifs. CID-078 selectively targets tumor cells with oncogenic alterations that cause cell cycle dysregulation, including alterations in the tumor suppressor RB1. In pre-clinical studies, Circle Pharma’s cyclin A/B RxL inhibitors have been shown to potently and selectively disrupt the protein-to-protein interaction between cyclins A and B and their key substrates and modulators, including E2F (a substrate of cyclin A) and MYT1 (a modulator of cyclin B). Preclinical studies have demonstrated the ability of these cyclin A/B RxL inhibitors to cause single-agent tumor regressions in multiple in vivo models. A multi-center Phase 1 clinical trial (NCT06577987) is currently enrolling patients with advanced solid tumors harboring RB1 alterations.
About Circle Pharma
Circle Pharma is a clinical-stage biopharmaceutical company harnessing the power of macrocycles to develop next-generation targeted therapies for cancer and other serious illnesses. The company’s proprietary MXMO™ platform overcomes key challenges in macrocycle drug development, enabling the creation of intrinsically cell-permeable and orally bioavailable therapies, including for historically undruggable targets. Circle Pharma’s pipeline is focused on targeting cyclins, key regulators of the cell cycle that drive many cancers. The company’s lead program, CID-078, is a cyclin A/B RxL inhibitor in Phase 1 clinical development for patients with advanced solid tumors. Circle Pharma is based in South San Francisco, CA. For additional information, please visit us at circlepharma.com and follow us on LinkedIn and X.
Contacts:
Media:
Josie Butler
1AB
Investors:
Steve Klass
1AB
SOUTH SAN FRANCISCO, CA, September 9, 2025 – Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for difficult-to-treat cancers, today announced an agreement with Eli Lilly and Company (Lilly) that enables the company to use Lilly TuneLab, a pioneering artificial intelligence and machine learning (AI/ML) platform designed to accelerate the development of new medicines by providing biotech companies access to powerful drug discovery models that have been trained on Lilly’s proprietary research data.
Circle Pharma will leverage Lilly TuneLab to further strengthen its AI/ML capabilities and proprietary MXMO™ platform, which is designed to overcome key challenges in macrocycle drug development to enable the creation of intrinsically cell-permeable and orally bioavailable macrocycle therapies, including for historically undruggable targets. Circle Pharma’s lead program, CID-078, is a first-in-class, orally bioavailable cyclin A/B RxL inhibitor that is being evaluated in a Phase 1 clinical trial for patients with advanced solid tumors.
“We are thrilled to partner with Lilly and gain access to TuneLab,” said Constantine Kreatsoulas, Ph.D., senior vice president, head of discovery technology sciences at Circle Pharma. “This collaboration will further enhance our MXMO™ platform, which enables us to better predict how various types of macrocycles may be able to penetrate cells, show oral bioavailability, exhibit desirable drug-like properties, and be manufactured at scale. This collaboration comes at an important time of growth at Circle Pharma with our lead program, CID-078, now in clinical development and our preclinical pipeline advancing rapidly to address cyclins and other historically undruggable targets in oncology.”
This agreement is part of the Lilly Catalyze360 model, a comprehensive approach to empower early-stage biotechs to advance groundbreaking science by providing access to capital, cutting-edge lab space and technology, and drug development talent and resources.
About Circle Pharma’s MXMO™ platform
Circle Pharma’s proprietary MXMO™ platform combines computationally driven drug design along with advanced, fully synthetic macrocycle chemistry. Through this platform, Circle Pharma’s scientists screen vast permeability-biased physical and virtual macrocycle libraries to identify early hit compounds. Artificial Intelligence (AI), Machine Learning (ML), and rigorous physics-based simulations are used to assess many designs simultaneously and to rapidly explore structure-activity relationships for hit-to-lead progression. These diverse compounds are then synthesized in the lab, utilizing both natural and unnatural chemical building blocks, many of which are custom and proprietary to Circle Pharma, to evaluate them as lead investigational macrocycles.
About Circle Pharma
Circle Pharma is a clinical-stage biopharmaceutical company harnessing the power of macrocycles to develop next-generation targeted therapies for cancer and other serious illnesses. The company’s proprietary MXMO™ platform overcomes key challenges in macrocycle drug development, enabling the creation of intrinsically cell-permeable and orally bioavailable therapies, including for historically undruggable targets. Circle Pharma’s pipeline is focused on targeting cyclins, key regulators of the cell cycle that drive many cancers. The company’s lead program, CID-078, is a cyclin A/B RxL inhibitor in Phase 1 clinical development for patients with advanced solid tumors. Circle Pharma is based in South San Francisco, CA. For additional information, please visit us at circlepharma.com and follow us on LinkedIn and X.
Contacts:
Media:
Josie Butler
1AB
Investors:
Steve Klass
1AB